Boron Analytical Studies on 10B1-BPA Administration for Neutron Capture Therapy of Malignant Melanoma

Success of boron neutron capture therapy (NCT) for cancer depends mainly upon selective boron accumulation in the targeted tumor. Since 1987 we have succeeded in treating human melanoma lesions by NCT utilizing10B1-para-boronophenylalanine (10B1-BPA).1 At the same time we have investigated various methods of administering10B1-BPA for optimal NCT. The results of our analytical studies on boron kinetics in animals and humans by 10B1-BPA administration are described.